Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)β’ Click on a phase to view related trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
- Conditions
- Prostate CancerProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer RecurrentProstate Cancer Patients Who Have Brachytherapy Seed ImplantProstate Cancer Patients Treated by RadiotherapyCryotherapy
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 220
- Registration Number
- NCT06970847
- Locations
- πΊπΈ
Biogenix Molecular, Miami, Florida, United States
πΊπΈThe Urology Place, San Antonio, Texas, United States
πΊπΈXCancer, Omaha, Nebraska, United States
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 383
- Registration Number
- NCT06056830
- Locations
- πΊπΈ
Indiana University School of Medicine, Indianapolis, Indiana, United States
πΊπΈMount Sinai Doctors Urology Faculty Practice, New York, New York, United States
πΊπΈUniversity of Texas Southwestern Medical Center, Dallas, Texas, United States
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
- Conditions
- Castration-ResistantProstatic Neoplasms
- Interventions
- Drug: 64Cu-SAR-BBN
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 4
- Registration Number
- NCT05633160
- Locations
- πΊπΈ
Stanford University, Stanford, California, United States
πΊπΈBiogenix Molecular, Miami, Florida, United States
πΊπΈBAMF Health, Inc, Grand Rapids, Michigan, United States
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- Drug: 64Cu-SAR-BBN
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 53
- Registration Number
- NCT05407311
- Locations
- πΊπΈ
Tower Urology, Los Angeles, California, United States
πΊπΈStanford University, Stanford, California, United States
πΊπΈBiogenix Molecular, Miami, Florida, United States
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
- Conditions
- Biochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Clarity Pharmaceuticals Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT05249127
- Locations
- πΊπΈ
Tower Urology, Los Angeles, California, United States
πΊπΈGU Research Network, Omaha, Nebraska, United States
πΊπΈNew Mexico Cancer Center, Albuquerque, New Mexico, United States
- Prev
- 1
- 2
- 3
- Next